American journal of respiratory cell and molecular biology · 2026
Combined inhibition of FABP4/5 ameliorates pulmonary hypertension by reducing pulmonary vascular and right ventricular fibrosis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Juan, Shen Yi, Qiu Xi, Lin Xiaojin, He Jiahao, Ren Ni, Yang Jianuo, Wang Guanli, Mo Zhanjie, Xiao Dakai, Liu Chunli
Аннотация
RATIONALE: Lipid metabolism disorder is increasingly recognized as hallmarks of pulmonary hypertension (PH). Fatty acid-binding proteins (FABPs), particularly FABP4 and FABP5, which regulate lipid transport and metabolism of fatty acid, are thought to contribute to the development of PH. However, it remains unclear whether FABP4 and FABP5 serve as therapeutic targets for the treatment of PH. Measurements and Main.
RESULTS: The levels of FABP4/5 were elevated in the plasma and lung tissues of idiopathic pulmonary arterial hypertension (IPAH) patients, as well as in the lung tissues of the PH rat model compared with control. The circulating levels of FABP4 of IPAH patients were correlated with mean pulmonary arterial pressure (mPAP). To determine the preventive or therapeutic effect of FABP4 and FABP5 inhibition, FABP4 and FABP5 inhibitors alone or combination were administered at early (days 2 following monocrotaline [MCT] injection) and late (day 12 following MCT injection) stage of PH rat model, respectively. Combined treatment with FABP4/5 inhibitors in the early stage of the MCT-PH rat model effectively reduced right ventricular systolic pressure (RVSP) and improved right ventricular (RV) function, accompanied by reductions in pulmonary vascular and RV fibrosis, as well as blood lipid levels, lipid peroxidation, and inflammation. Combined treatment with FABP4/5 inhibitors at the late stage of MCT-PH improved RV function, suppressed pulmonary vascular and RV fibrosis, and lowered blood lipid levels, but did not affect RVSP.
CONCLUSIONS: Combined inhibition of FABP4 and FABP5 can prevent the pathogenesis of PH, representing a potential therapeutic strategy for PH. p.
RESULTS: The levels of FABP4/5 were elevated in the plasma and lung tissues of idiopathic pulmonary arterial hypertension (IPAH) patients, as well as in the lung tissues of the PH rat model compared with control. The circulating levels of FABP4 of IPAH patients were correlated with mean pulmonary arterial pressure (mPAP). To determine the preventive or therapeutic effect of FABP4 and FABP5 inhibition, FABP4 and FABP5 inhibitors alone or combination were administered at early (days 2 following monocrotaline [MCT] injection) and late (day 12 following MCT injection) stage of PH rat model, respectively. Combined treatment with FABP4/5 inhibitors in the early stage of the MCT-PH rat model effectively reduced right ventricular systolic pressure (RVSP) and improved right ventricular (RV) function, accompanied by reductions in pulmonary vascular and RV fibrosis, as well as blood lipid levels, lipid peroxidation, and inflammation. Combined treatment with FABP4/5 inhibitors at the late stage of MCT-PH improved RV function, suppressed pulmonary vascular and RV fibrosis, and lowered blood lipid levels, but did not affect RVSP.
CONCLUSIONS: Combined inhibition of FABP4 and FABP5 can prevent the pathogenesis of PH, representing a potential therapeutic strategy for PH. p.